IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of “Moderate Buy” by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $46.60.

Several equities research analysts have commented on IDYA shares. The Goldman Sachs Group boosted their price target on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 21st. BTIG Research reaffirmed a “buy” rating and issued a $62.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. UBS Group started coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Wall Street Zen raised IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 9th.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock opened at $34.06 on Tuesday. The firm has a market cap of $2.99 billion, a PE ratio of -18.31 and a beta of 0.10. The business’s 50 day simple moving average is $34.99 and its 200 day simple moving average is $29.81. IDEAYA Biosciences has a 52-week low of $13.45 and a 52-week high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, topping the consensus estimate of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to the consensus estimate of $59.98 million. As a group, equities research analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Trading of IDEAYA Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D lifted its holdings in IDEAYA Biosciences by 11.1% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 100,827 shares of the company’s stock valued at $2,119,000 after purchasing an additional 10,047 shares during the last quarter. General American Investors Co. Inc. increased its holdings in shares of IDEAYA Biosciences by 7.7% in the third quarter. General American Investors Co. Inc. now owns 280,261 shares of the company’s stock valued at $7,626,000 after purchasing an additional 20,000 shares during the last quarter. Creative Planning raised its position in shares of IDEAYA Biosciences by 99.4% in the second quarter. Creative Planning now owns 121,684 shares of the company’s stock valued at $2,558,000 after purchasing an additional 60,667 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of IDEAYA Biosciences by 19.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 13,787 shares of the company’s stock worth $290,000 after buying an additional 2,227 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC bought a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth about $934,000. 98.29% of the stock is owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.